http://rdf.ncbi.nlm.nih.gov/pubchem/reference/35832177

Outgoing Links

Predicate Object
contentType Journal Article
issn 2666-3643
issueIdentifier 5
pageRange 100508-
publicationName JTO Clinical and Research Reports
startingPage 100508
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c1b9f1c2d5cc1361ccf28b0108bd7179
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f3daea6705397bee74bf977fb3859043
bibliographicCitation Goto Y, Kenmotsu H, Tamiya M, Murakami S, Kurata T, Yanagitani N, Taniguchi H, Kuyama S, Shimizu J, Yokoyama T, Shimada N, Maeda T, Tamiya A, Uchiyama A, Imaizumi K, Takahama T, Kato T, Hayashi H, Shiraiwa N, Toyoizumi S, Kikkawa H, Thomaidou D, Nishio M. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan. JTO Clinical and Research Reports. 2023 May;4(5):100508. doi: 10.1016/j.jtocrr.2023.100508.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea80106eec97dec6f97e8d4ddbaa7ead
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b8a6151c98066d02943deddac8e3901
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ac1de30a6812e3ccbd6403894523dbc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa4d5cfbefb183ef405a98c81ea9210a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0ed74df9af60c4da2b88907f0050cdca
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2430de22308d6aeb39fd683d90459ff6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d706cfd2b99747155ec5f10bb77e25cf
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b4acb05bbcd69a500017f294a37ddda
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b39a6707fba28a2c0e6bc4598b776b8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3f63141403785cf0c6d8446487662de
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7437-5054
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0028d9fcd1cf52731adda81766233e6a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3302670bb3237147f74b27e8892a22d4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_95abd00cceda80b351c54b32479d241d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65269f61e763caf2fa4efdc127c74b63
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c7572998b2f0d1b09b87e5501251379
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_138f4ca374f02614085368d12fdbccda
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a6674957f70edb41029936ac06d9479e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffb8c7b75c11123670b7685e2d063882
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6955cb3a54e2ea5f757046f8aac25a2b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03be562e10ec8a01fe771e5b4e9a0767
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_70ccf082e9c4b79f5c26f079595d10b9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6670b992115534211622e570a693e4ab
date 202305
identifier https://pubmed.ncbi.nlm.nih.gov/PMC10209333
https://doi.org/10.1016/j.jtocrr.2023.100508
https://pubmed.ncbi.nlm.nih.gov/37250506
isPartOf https://portal.issn.org/resource/ISSN/2666-3643
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/49842
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7099
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71731823
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID49806720

Showing number of triples: 1 to 47 of 47.